Siru Nie

Dr. Siru Nie

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 July 2020 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
SNSiru Nie
Siru Nie
YYYuan Yuan
Yuan Yuan
Gastric mucosa plays its immune function through innate and adaptive immunity by recruiting immune cells and releasing corresponding cytokines, which have an inseparable relationship with gastric diseases. Whether infective gastric diseases caused by Helicobacter pylori, Epstein-Barr virus or other microbe, noninfective gastric diseases, or gastric cancer, gastric mucosal immunity plays an important role in the occurrence and development of the disease. Understanding the unique immune-related tissue structure of the gastric mucosa and its role in immune responses can help prevent gastric diseases or treat them through immunotherapy. In this review, we summarize the basic feature of gastric mucosal immunity and its relationship with gastric diseases to track the latest progress of gastric mucosal immunity, update relevant knowledge and provide theoretical reference for the prevention and treatment of gastric diseases based on the gastric mucosal immunity.

3 November 2023 in Cancers
Verified
Journal Article
Open access
PDF file
SNSiru Nie
Siru Nie
AWAng Wang
Ang Wang
XCXiaohui Chen
Xiaohui Chen
YGYuehua Gong
Yuehua Gong
YYYuan Yuan
Yuan Yuan
Metabolites associated with microbes regulate human immunity, inhibit bacterial colonization, and promote pathogenicity. Integrating microbe and metabolome research in GC provides a direction for understanding the microbe-associated pathophysiological process of metabolic changes and disease occurrence. The present study included 30 GC patients with 30 cancerous tissues and paired non-cancerous tissues (NCs) as controls. LC-MS/MS metabolomics and 16S rRNA sequencing were performed to obtain the metabolic and microbial characteristics. Integrated analysis of the microbes and metabolomes was conducted to explore the coexistence relationship between the microbial and metabolic characteristics of GC and to identify microbial-related metabolite diagnostic markers. The metabolic analysis showed that the overall metabolite distribution differed between the GC tissues and the NC tissues: 25 metabolites were enriched in the NC tissues and 42 metabolites were enriched in the GC tissues. The α and β microbial diversities were higher in the GC tissues than in the NC tissues, with 11 differential phyla and 52 differential genera. In the correlation and coexistence integrated analysis, 66 differential metabolites were correlated and coexisted, with specific differential microbes. The microbes in the GC tissue likely regulated eight metabolic pathways. In the efficacy evaluation of the microbial-related differential metabolites in the diagnosis of GC, 12 differential metabolites (area under the curve [AUC] >0.9) exerted relatively high diagnostic efficiency, and the combined diagnostic efficacy of 5 to 6 microbial-related differential metabolites was higher than the diagnostic efficacy of a single feature. Therefore, microbial diversity and metabolite distribution differed between the GC tissues and the NC tissues. Microbial-related metabolites may be involved in eight major metabolism-based biological processes in GC and represent potential diagnostic markers.

15 August 2025 in Microorganisms
Verified
Journal Article
Open access
PDF file
SNSiru Nie
Siru Nie
YGYuehua Gong
Yuehua Gong
AWAng Wang
Ang Wang
RGRui Guo
Rui Guo
XCXiaohui Chen
Xiaohui Chen
YYYuan Yuan
Yuan Yuan
The colonization of Fusobacterium nucleatum (F. nucleatum) in the microenvironment of gastric cancer (GC) is closely associated with tumor progression, but its impact on host metabolic remodeling remains unclear. This study aims to elucidate the mechanistic link between F. nucleatum infection and metabolic changes in GC tissue. By integrating 16S rRNA microbiome sequencing and LC-MS/MS metabolomics, the differences in microbial composition and metabolic profiles between Fusobacterium sp.-positive and -negative GC tissues were systematically compared, and the correlation of differential microbes and differential metabolites was analyzed. The impact of F. nucleatum on the glutathione (GSH) metabolic pathway was validated through in vitro tissue testing and the use of the infection model of GC cell lines (such as AGS and HGC27). Integrative omics analysis showed a strong negative correlation between Fusobacterium sp. infection and antioxidant metabolite GSH levels in GCs (p < 0.001). Metabolic reprogramming features: Eleven differentially expressed metabolites were identified using LC-MS/MS metabolomics screening (p < 0.05). GSH was significantly depleted in the Fusobacterium sp.-positive group. Experimental validation: At the histological level, the abundance of F. nucleatum in GC tissues was higher than that in the paired adjacent non-cancerous (NC) tissues; at the cellular level, after F. nucleatum infection of GC cells, the intracellular GSH level decreased (p < 0.01), accompanied by a decrease in glutathione synthetase (GSS) mRNA expression and reactive oxygen species (ROS). This study is the first to demonstrate that F. nucleatum suppresses the GSH synthesis pathway, leading to the breakdown of antioxidant capacity and the formation of an oxidative stress microenvironment in GC cells. These findings provide new insights into the metabolic mechanism of F. nucleatum in promoting GC progression and suggest that targeting the F. nucleatum-GSH axis could offer a novel strategy for GC therapeutic intervention.

18 October 2026 in Life
Verified
Journal Article
Open access
PDF file
YAYini Alatan
Yini Alatan
FZFenghao Zheng
Fenghao Zheng
PYPeiling Yu
Peiling Yu
YYYinan Yuan
Yinan Yuan
HGHongyu Guo
Hongyu Guo
YMYuan Miao
Yuan Miao
Plasmablastic/anaplastic plasma cell neoplasms (P/APC-N) and plasmablastic lymphoma (PBL) represent two categories of highly aggressive hematolymphoid malignancies. Their distinction is clinically important because they are classified and treated within different disease frameworks, yet no single morphologic, immunophenotypic, viral, cytogenetic, or molecular finding reliably resolves all cases. The proposed approach begins with the clinical and systemic context, including a pre-existing plasma cell neoplasm, marrow and serum findings, myeloma-defining events, immune status, and disease distribution. Morphologic assessment is followed by a panel evaluating plasma-cell differentiation, conventional B-cell markers, light-chain restriction, proliferative activity, and tumor-cell Epstein–Barr virus-encoded RNA (EBER) by in situ hybridization. Evidence of an established plasma cell neoplasm and a coherent myeloma-associated genomic background favor the relevant plasma cell neoplasm subtype, whereas tumor-cell EBER positivity in a compatible context supports PBL but is not specific. MYC protein overexpression, MYC rearrangement, high proliferative activity, light-chain restriction, and loss of conventional B-cell markers can occur in both categories and should not be used as stand-alone discriminators. When evidence does not converge, reports should state the findings favoring each category, identify unresolved conflicts, and recommend the next diagnostic steps. This framework remains to be validated in independent cohorts.